Discontinuation of oral antivirals in chronic hepatitis B: A systematic review (Q38813725)

6 September 2017

Discontinuation of oral antivirals in chronic hepatitis B: A systematic review (English)

1 reference

6 September 2017

1 reference

1 reference

1 reference

George Papatheodoridis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27100145%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Evangelos Cholongitas

3

object named as

Evangelos Cholongitas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27100145%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Ioannis Vlachogiannakos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27100145%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Karsten Wursthorn

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27100145%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Christos Thomadakis

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27100145%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Giota Touloumi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27100145%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Jörg Petersen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27100145%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

language of work or name

English

0 references

publication date

4 March 2016

1 reference

6 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27100145%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

63

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27100145%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

1481-1492

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27100145%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27100145%20AND%20SRC:MED&resulttype=core&format=json

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

4 June 2020

cites work

1 reference

7 January 2021

Chronic hepatitis B: update 2009

1 reference

7 January 2021

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.

1 reference

7 January 2021

Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?

1 reference

7 January 2021

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

1 reference

7 January 2021

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

1 reference

7 January 2021

Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy?

1 reference

7 January 2021

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

1 reference

7 January 2021

Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

7 January 2021

Optimal duration of additional therapy after biochemical and virological responses to lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomized trial.

1 reference

7 January 2021

Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.

1 reference

7 January 2021

The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.

1 reference

7 January 2021

Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients

1 reference

7 January 2021

Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion

1 reference

7 January 2021

On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients

1 reference

7 January 2021

Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients

1 reference

7 January 2021

Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients

1 reference

7 January 2021

Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients

1 reference

7 January 2021

High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy

1 reference

7 January 2021

Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir

1 reference

7 January 2021

A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir

1 reference

7 January 2021

Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B.

1 reference

7 January 2021

Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative

1 reference

7 January 2021

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients

1 reference

7 January 2021

Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients

1 reference

7 January 2021

Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment?

1 reference

7 January 2021

Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir

1 reference

7 January 2021

Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs

1 reference

7 January 2021

Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.

1 reference

7 January 2021

Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients

1 reference

7 January 2021

The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment

1 reference

7 January 2021

Residual amount of HBV DNA in serum is related to relapse in chronic hepatitis B patients after cessation of nucleos(t)ide analogs

1 reference

7 January 2021

Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study

1 reference

7 January 2021

Effects of adjusting for censoring on meta-analyses of time-to-event outcomes.

1 reference

7 January 2021

Two-stage meta-analysis of survival data from individual participants using percentile ratios.

1 reference

7 January 2021

Relapse of chronic hepatitis B after discontinuation of nucleos(t)ide analogs: is the glass half full or half empty?

1 reference

7 January 2021

Discontinuation of long-term NA therapy in HBeAg-negative chronic hepatitis B

1 reference

7 January 2021

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.28438

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27100145%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference